title: Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders.
abstract: OBJECTIVE
  Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment.
  
  
  METHODS
  All patients received interferon alfa2a (5MU/m(2)) thrice weekly for 6 months; children with genotype 1b received 3MU/m(2) thrice weekly for 6 additional months.
  
  
  RESULTS
  Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19%, intention to treat analysis), including 2/20 (10%) with genotype 1b and 6/12 (50%) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean+/-S.D.: 44.7+/-14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis.
  
  
  CONCLUSIONS
  Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.
authors.affiliation: Clinica Medica 5, University, Padua, Italy. flavia.bortolotti@unipd.it
authors.forename: F
authors.initials: F
authors.lastname: Bortolotti
authors.forename: R
authors.initials: R
authors.lastname: Iorio
authors.forename: G
authors.initials: G
authors.lastname: Nebbia
authors.forename: M
authors.initials: M
authors.lastname: Marcellini
authors.forename: R
authors.initials: R
authors.lastname: Giacchino
authors.forename: L
authors.initials: L
authors.lastname: Zancan
authors.forename: N
authors.initials: N
authors.lastname: Gussetti
authors.forename: C
authors.initials: C
authors.lastname: Barbera
authors.forename: A
authors.initials: A
authors.lastname: Maccabruni
authors.forename: G
authors.initials: G
authors.lastname: Verucchi
authors.forename: F
authors.initials: F
authors.lastname: Balli
authors.forename: A
authors.initials: A
authors.lastname: Vegnente
authors.forename: M
authors.initials: M
authors.lastname: Guido
authors.forename: S
authors.initials: S
authors.lastname: Bartolacci
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins